Non-Small Cell Lung Carcinoma
WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, EGFR-mutated NSCLC, MARIPOSA study, WCLC24, survival benefit, first-line treatment.
AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches
NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment
AstraZeneca and Gilead Explore TROP2 ADCs in Lung Cancer, Seeking Pathways to Approval
TROP2 ADCs, Lung Cancer, AstraZeneca, Gilead, Datopotamab Deruxtecan, Trodelvy, Non-Small Cell Lung Cancer (NSCLC)
Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%
Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.
Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer
Rybrevant (amivantamab-vmjw), Lazcluze (lazertinib), Tagrisso (osimertinib), EGFR-mutated lung cancer, Non-small cell lung cancer (NSCLC), MARIPOSA study, Survival analysis, Chemotherapy-free treatment
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen
FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery
FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC
FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website
Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment
Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials
Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer
FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC
AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy